Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter comparative study between nutritional therapy alone and infliximab in moderate-to-severe active Crohn's disease
2008-006484-36Phase 3Terminated
- Sponsor
- Azienda Ospedaliero-Universitaria Policlinico Umberto I
- Start
- Apr 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of infliximab in Crohn's disease (2 arms), sponsored by Azienda Ospedaliero-Universitaria Policlinico Umberto I. Primary endpoints: Combined clinical remission and intestinal mucosal healing at end of induction and Combined clinical remission and intestinal mucosal healing at end of maintenance. Started Apr 2009; status: terminated.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2008-006484-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006484-36.